The MCF is one of four contracts used by the Contraceptive Discovery and Development Branch (CDDB), formerly the Contraception and Reproductive Health (CRH) Branch, to support research on the discovery, optimization, and development of male and female contraceptive agents.
This facility provides NICHD-supported researchers and other investigators with technology, infrastructure, and know-how for drug discovery and optimization. The MCF utilizes high-throughput screening (HTS) assays of compound libraries to lead discoveries that inhibit validated male and female contraceptive targets. A targeted library may be synthesized for further testing for cases where a lead has been identified. The MCF carries out a further optimization step that encompasses modeling and structure biology with iterative synthesis and biological testing for achieving highly specific and potent drug candidates. The lead optimization steps revolve around structure- based drug design (SBDD) where modeling, structure biology, synthesis, and biological assays play critical roles in the iterative process of determining optimal structure and activity.
The MCF is engaged in early discovery for optimization of small molecules directed at validated male and female contraceptive targets.